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Abstract
Though endoscopic treatment is an option for T1 colorectal cancer (CRC), the optimal indications and long-term outcomes of this
strategy need to be validated. Therefore, the aim of this study is to investigate long-term outcomes of endoscopy versus surgery and
optimal indications for endoscopic treatment of T1 CRC.
This retrospective study included 428 T1 CRC patients treated with initial endoscopy (n=224) or surgery (n=204) at Severance
Hospital between 2005 and 2012. Patients were subdivided into 4 groups according to conventional indications (CIs) for endoscopic
treatment: negative lateral/vertical margins; submucosal invasion depth within 1000mm; no lymphovascular invasion (LVI); well or
moderately differentiated. For prognosis evaluation, short-term outcomes (resection margin and complications) and long-term
outcomes (recurrence and cancer-speciﬁc mortality) were evaluated.
Endoscopic treatment achieved en bloc resection in 86.6% of 224 patients. Recurrence and mortality did not differ between the
endoscopy and surgery groups with or without CIs. For patients with CIs, although 80 patients were treated endoscopically with 1
(1.3%) recurrence and 0 mortality, 75 patients were treated surgically with 2 (2.7%) recurrence and 1 (1.3%) mortality. Multivariate
analysis revealed that LVI positivity and poorly differentiated histology were independently associated with lymph node metastasis
(LNM; P<0.001 and P=0.001, respectively).
To determine whether the depth of submucosal invasion among criteria of CIs could be extended for endoscopic treatment, LNM
was analyzed by extending the depth of submucosal invasion. There was no LNM in 155 patients within conventional indication.
When the depth of submucosal invasion was extended up to 1500mm, LNM was occurred (1/197 patient [0.5%]). In addition, when
the depth of submucosal invasion was extended up to 2000mm, LNM was increased (4/271 patient [1.5%]).
Endoscopic treatment is safe, effective, and is associatedwith favorable long-term outcomes compared to surgery for initial treatment
of T1 CRC patients with CIs. However, the risk of LNM makes it unsafe to extend the CIs for endoscopic therapy in these patients.
Abbreviations: CEA = carcinoembryonic antigen, CIs = conventional indications, CRC = colorectal cancer, ECC = early
colorectal cancer, EMR = endoscopic mucosal resection, ESD = endoscopic submucosal dissection, ET-CI group = endoscopic
therapy with conventional indications group, ET-NCI group = endoscopic therapy with nonconventional indications group, LNM =
lymph node metastasis, LVI = lymphovascular invasion, OR = odds ratio, ST-CI group = surgical therapy with conventional
indications group, ST-NCI group = surgical therapy with non-conventional indications group.
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11. Introduction
Colorectal cancer (CRC) is one of the most common malignan-
cies in both Asian and Western countries.[1,2] A vigorous CRC
screening program and improvements in endoscopic techniques
have led to an increase in the proportion of colorectal cancer
cases that are diagnosed at early stages.[3–5] As a result, the
incidence of T1 CRC has increased, and some T1 CRC patients
are candidates for endoscopic treatment.[6,7] However, 6% to
12% of T1 CRC patients experience lymph node metastasis
(LNM), which requires subsequent surgical resection.[8–10]
Though the likelihood of LNM in T1 CRC patients is low,
surgical resection and removal of regional lymph nodes is
considered the deﬁnitive treatment for this disease.[11]
Many studies have been performed in recent decades to
validate clinical and histological factors that predict LNM, as this
knowledge is needed to establish the proper indications for
endoscopic treatment of T1 CRC.[12–15] According to the Paris
classiﬁcation and Japanese clinical guidelines, CRC is considered
to be low-risk for LNM and local recurrence if it is submucosal
Kim et al. Medicine (2016) 95:37 Medicineinvasive CRC with negative vertical margins, well or moderately
differentiated adenocarcinoma, lacks evidence of vascular or
lymphatic invasion, and has an invasion depth <1000mm.[16,17]
Endoscopic resection is commonly performed for low-risk T1
CRC based on these guidelines, and these histologic factors are
considered to be the conventional indications (CIs) for
endoscopic treatment alone. Recent studies have reported the
feasibility and favorable short-term outcomes of endoscopic
treatment for T1 CRC.[18–20] However, the long-term outcomes
of endoscopic treatment compared to surgery are not well-
established. Furthermore, although the expanded indications
have been applied to the endoscopic treatment of early gastric
cancer,[21–23] there are no data about the expanded indications
for endoscopic treatment of T1 CRC.
The present study focused on these points by evaluating long-
term outcomes of T1 CRC patients treated endoscopically
compared to patients treated surgically and determined the
optimal indications for endoscopic treatment with respect to the
risk of LNM.
2. Methods
2.1. Patients
The present study included 549 patients who were diagnosed
with cT1N0 CRC at Severance Hospital between January 2005
and March 2012. A total of 121 patients were excluded because:
they had other coexisting malignancies within 5 years before
CRC diagnosis (n=32); they had coexisting synchronous
advanced CRC (n=5); they were lost to follow-up (n=22);
there were insufﬁcient pathology reports (n=46); they received
neoadjuvant therapy before surgery (n=15); or they had familial
adenomatous polyposis, hereditary nonpolyposis colorectal
cancer, or inﬂammatory bowel disease (n=1). Finally, 428
patients with T1 CRC who underwent endoscopic (n=224) orFigure 1. Clinical courses of 428 patients with T1 colorectal cancer treated by end
subdivided into 4 groups based on whether or not their lesions satisﬁed the co
indications and underwent initial endoscopic treatment, 13 patients (16.3%) unde
144 patients with nonconventional indications who underwent initial endoscop
experienced recurrence, and there was 1 (0.7%) mortality. For the initial surgical
mortality among the 75 conventional indication cases, and 7 patients (5.4%) with
cases. ECC=early colorectal cancer, F/U= follow-up, LN= lymph node, LVI= lymph
resection margin. †Conventional indications: patients who underwent curative res
lateral/vertical margins; submucosal invasion depth within 1000mm; no lymphova
2surgical (n=204) initial treatment were included in the study. The
patients were subdivided into 4 groups according to CIs:
endoscopic therapy with CIs (ET-CI group), endoscopic therapy
with non-conventional indications (ET-NCI group), surgical
therapy with CIs (ST-CI group), and surgical therapy with non-
conventional indications (ST-NCI group) (Fig. 1).
The CIs were: negative lateral/vertical margins; submucosal
invasion depth <1000mm; no lymphovascular invasion (LVI);
well or moderately differentiated.
The institutional review board approved the study protocol.
All study procedures were conducted in accordance with the
International Conference on Harmonization Good Clinical
Practices and the Declaration of Helsinki and its amendments.2.2. Procedures
2.2.1. Endoscopic treatment. Endoscopic procedures were
performed using a single-channel colonoscope (CF Q240L, CF
Q240I, CF H260AI, CF Q260AI, or PCF Q260AI; Olympus
Optical Co., Tokyo, Japan) and a high-frequency generator with
an automatically controlled system (VIO300; ERBE Elektrome-
dizin GmbH, Tubingen, Germany). All procedures were
performed by 4 experienced gastroenterologists. Endoscopic
treatments, including endoscopic mucosal resection (EMR) and
endoscopic submucosal dissection (ESD), were chosen based on
the characteristics of the lesion and the preference of the
operating physician. EMR was performed using a snare after
injecting solution (normal saline, 0.04% indigo carmine, with or
without 1:100,000 diluted epinephrine) into the submucosa. If
tumors remained, sequential submucosal injection and snare
polypectomies were performed. ESD was performed with a ﬂex
knife (Flex Knife; KD-630L, Olympus Optical Co.) or a dual
knife (Dual Knife; KD-650L, Olympus Optical Co.). After
spraying the lesion with 0.4% indigo carmine dye and injecting
solution into the submucosa beneath the lesion, a knife was usedoscopy (n=224) or surgery (n=204) as the initial treatment. The patients were
nventional indications. Among the 80 patients who satisﬁed the conventional
rwent additional surgery and 1 patient (1.3%) experienced recurrence. Among
ic treatment, 130 patients underwent additional surgery, 4 patients (2.8%)
treatment groups, there were 2 patients (2.7%) with recurrence and 1 (1.3%)
recurrence and 4 (3.1%) mortalities among the 129 nonconventional indication
ovascular invasion, MM=muscularis mucosa, PD=poorly differentiated, RM=
ection by endoscopy or surgery. The conventional indications were: negative
scular invasion; well- or moderately differentiated tumors.
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additional injection beneath the lesion to lift it up from the
muscularis propria, a knife was used to directly dissect the
submucosal layer. If a residual lesion was detected endoscopi-
cally, additional EMR was performed. Resections were classiﬁed
as either en bloc resection (resection in a single piece) or piecemeal
resection (resection in multiple pieces).
2.2.2. Surgical treatment. Laparoscopic and open surgeries
were performed by experienced colorectal surgeons. The type of
surgery (right hemi-colectomy, left hemi-colectomy, segmentec-
tomy, anterior resection, low anterior resection, or abdomino-
perineal resection) was determined based on the tumor site and at
the discretion of the surgeon. For patients with NCIs in the
pathology analysis after endoscopic resection, an additional
curative surgical resection with lymph node dissection was
recommended.2.3. Main outcome measurements
To evaluate adverse events, we analyzed perforations,
intestinal obstructions, and pneumonia using simple chest
and abdominal x-rays that were taken immediately after
endoscopies or surgeries. Immediate bleeding was determined
by endoscopic ﬁndings during the procedure (continued for
over 60 seconds), and late bleeding was determined by clinical
symptoms, vital signs, and laboratory tests after the procedure
(within 30 days of the procedure and required hospitalization
or treatment).
To check the resection status, all resected specimens were cut
into 2-mm-wide longitudinal slices. Experienced gastrointestinal
pathologists evaluated all pathologic specimens for resection
margin status and tumor characteristics, including histologic
type, depth of invasion, vascular invasion, and lymphatic
invasion. Histologic diagnoses were determined and measure-
ments of tumor invasion depth were obtained according to the
guidelines of the Japanese Society for Cancer of the Colon and
Rectum.[17]
For evaluation of long-term outcomes, we considered physical
examinations, blood tests (including measurement of carcinoem-
bryonic antigen [CEA] levels), chest radiography, and computed
tomography scans of the abdomen and pelvis taken after
endoscopic or surgical treatment during follow-up visits every 6
months for the ﬁrst 2 years, and every year thereafter until 5
years. A colonoscopy was performed within a year after
endoscopic or surgical treatment. Recurrence was diagnosed
by radiologic images or positive biopsies. Mortality was
conﬁrmed using information from the national cancer registry
of Korea.2.4. Statistical analysis
Continuous variables are expressed as the mean± standard
deviation and categorical variables are expressed as number (%).
In the univariate analyses, baseline characteristics of each group
(initial endoscopic treatment vs. initial surgical treatment and
LNM negative vs. LNM positive) were compared using Student t
test for continuous variables and x2 tests or Fisher exact tests for
categorical variables. The Kaplan–Meier method was used to
estimate the distribution of the time from diagnosis to recurrence
or mortality according to independent variables. In the
multivariate analysis, binomial logistic regression analysis was
used to analyze the factors that affected LNM. Results were3considered to be statistically signiﬁcant if P<0.05. All statistical
analyses were performed using SPSS version 18.0 (SPSS Inc.,
Chicago, IL).3. Results
3.1. Baseline characteristics of included patients
The 428 T1 CRC patients in this study were divided into 4
groups based on their initial treatment modality and whether or
not they satisﬁed the CIs: the ET-CI group (n=80), the ST-CI
group (n=75), the ET-NCI group (n=144), and the ST-NCI
group (n=129). The mean follow-up duration was >40
months for all 4 groups and >3.5 years for all patients
(Table 1).
The baseline characteristics of included patients are described
in Table 1. In patients with the CIs, there were no signiﬁcant
differences in baseline characteristics including age, sex,
morphology, and histologic differentiation of T1 CRC between
the endoscopy and surgery groups. Mean tumor size was
signiﬁcantly larger in the surgery group compared to the
endoscopy group (23.7±14.4mm vs. 18.1±9.2mm; P=
0.005). With regard to tumor location, rectal lesions tended to
be more frequent in the surgery group compared to the
endoscopy group (46.7% vs. 37.5%; P=0.071).
Among the 80 ET-CI patients, 71 patients (88.7%) underwent
EMR and 9 patients (11.3%) were treated with ESD. En bloc
resection was achieved in 72 patients (90%), whereas 8 patients
(10.0%) had piecemeal resections (Table 1). All 75 ST-CI patients
had en bloc resections. The duration of follow-up was not
different between the 2 groups.3.2. Clinical outcomes of endoscopic treatment compared
to surgery in T1 CRC
Adverse events in the endoscopy group included delayed bleeding
in 1 patient (0.4%) and bowel perforations in 2 patients (0.9%),
which were successfully treated endoscopically (Table 2). Among
the 80 ET-CI patients, 14 patients (17.5%) underwent additional
surgeries because of the willingness of the patients. Among the
144 ET-NCI patients, 130 patients (89.6%) underwent addi-
tional surgeries, whereas additional surgeries were not performed
in 15 patients (10.4%) because of patient refusal or poor medical
condition.
Eventually, 347 patients underwent surgery: there were
9 patients with anastomosis site leakage (2.6%), 3patients
with intestinal obstruction (0.9%), and 1 patient each with
urinary dysfunction, pneumonia, and mortality (0.3% for
each).
There were no differences in recurrence or mortality between
the endoscopic and surgical therapy groups, with or without CIs
(recurrence: P=0.611 and P=0.192; mortality: P=0.484 and
P=0.267, respectively). Among the 80 ET-CI patients, there was
only 1 patient (1.3%) with recurrence and no mortalities. Among
the 75 ST-CI patients, there were 2 patients (2.7%) with
recurrence and 1 with (1.3%) mortality. In the NCI group, there
were 4 patients (2.8%) and 7 patients (5.4%) with recurrence in
the endoscopic and surgical therapy groups, respectively, and
there were 1 (0.7%) and 4 (3.1%) mortalities in the endoscopic
and surgical therapy groups, respectively. For the 4 mortalities in
the ST-NCI group, 1 was because of a surgical adverse event, and
the others were because of cancer recurrence and progression
(Table 2).
Table 1
Comparison of baseline characteristics between T1 colorectal cancer patients who underwent initial endoscopic treatment or initial
surgery.
Conventional indications (n=155)
∗
Non-conventional indications (n=273)
Initial therapy Endoscopy (n=80) Surgery (n=75) P Endoscopy (n=144) Surgery (n=129) P
Age (mean±SD), y 62.9±10.5 62.9±9.9 0.998 62.3±10.6 62.5±10.1 0.845
Male, n (%) 52 (65.0) 45 (60.0) 0.520 86 (59.7) 79 (61.2) 0.798
Location, n (%)† 0.071 0.003
Right 17 (21.3) 22 (29.3) 26 (18.1) 24 (18.6)
Left 33 (41.3) 18 (24.0) 66 (45.8) 35 (27.1)
Rectum 30 (37.5) 35 (46.7) 52 (36.1) 70 (54.3)
Size (mean±SD), mm 18.1±9.2 23.7±14.4 0.005 18.6±8.8 23.9±11.5 <0.001
Morphology, n (%)‡ 0.388 0.017
Is 51 (63.7) 42 (56.0) 100 (69.4) 69 (53.5)
IIa 27 (33.8) 33 (44.0) 40 (27.8) 51 (39.5)
IIa+ IIc 2 (2.5) 0 (0.0) 4 (2.8) 9 (7.0)
Histologic dif., n (%)x (n=79) (n=74) 0.849 (n=143) (n=129) <0.001
G1 49 (62.0) 47 (63.5) 67 (46.9) 39 (30.2)
G2 30 (38.0) 27 (36.5) 70 (49.0) 90 (69.8)
G3 6 (4.2) 0 (0.0)
LVI+, n (%) (n=130) 24 (18.5) (n=127) 13 (10.2) 0.060
Endoscopic therapy method, n (%)
EMR 71 (88.7) 131 (91.0)
ESD 9 (11.3) 13 (9.0)
Resection type, n (%)
En bloc 72 (90.0) 122 (84.7)
Piecemeal 8 (10.0) 22 (15.3)
F/U duration (mean±SD), mo 40.4±20.6 44.3±22.6 0.264 43.4±21.5 46.2±19.3 0.267
Variables are expressed as mean±SD or n (%). EMR= endoscopic mucosal resection, ESD= endoscopic submucosal dissection, F/U= follow-up, G=grade, histologic dif=histologic differentiation, LVI=
lymphovascular invasion, SD= standard deviation, SM= submucosa.
∗
Conventional indications: patients that underwent curative resection by endoscopic or surgical therapy. The conventional indications were: negative lateral/vertical margins; submucosal invasion depth within
1000mm; no lymphovascular invasion; well or moderately differentiated tumors.
† Right-sided colon was deﬁned as the region from the cecum to the transverse colon. Left-sided colon was deﬁned as the region from the splenic ﬂexure to the rectosigmoid junction. Rectum was deﬁned as the
region distal to the rectosigmoid junction to the anus.
‡Morphology was classiﬁed using the Paris classiﬁcation.
x G1 tumors are deﬁned as well differentiated, G2 tumors as moderately differentiated, G3 tumors as poorly differentiated.
Table 2
Comparison of procedure- or surgery-related adverse events and prognosis among T1 colorectal cancer patients who underwent initial
endoscopic treatment or surgery.
Endoscopy (n=224) Surgery (n=204)
Conventional
indications (n=80)
∗
Nonconventional
indications (n=144)
Conventional
indications (n=75)
∗
Nonconventional
indications (n=129) P
Endoscopy AE, n (%) 0.486
Immediate bleeding 13 (16.3) 16 (11.1)
Delayed bleeding 0 1 (0.7)
Bowel perforation 0 2 (1.4)
Additional surgery, n (%) 14 (17.5) 129 (89.6)
Surgery AE, n (%) (n=14) (n=129) 0.113†
Anastomosis site leakage 0 2 (1.6) 3 (4.0) 4 (3.1)
Intestinal obstruction 0 1 (0.8) 1 (1.3) 1 (0.8)
Urinary dysfunction 0 0 0 1 (0.8)
Pneumonia 0 0 0 1 (0.8)
LN metastasis, n (%) 11 (7.6) 8 (6.2) 0.621jj
Recurrence, n (%) 1 (1.3) 2 (2.7) 0.611x
4 (2.8) 7 (5.4) 0.192jj
Mortality, n (%) 0 1 (1.3) 0.484x
1 (0.7) 4 (3.1) 0.267jj
Procedure-related mortality, n (%) 0 0 0 1 (0.8)
Variables are expressed as n (%). AE= adverse event, LN= lymph node.
∗
Conventional indications: patients who underwent curative resection by endoscopy or surgery. The conventional indications were: negative lateral/vertical margin; submucosal invasion depth within 1000mm; no
lymphovascular invasion; well or moderately differentiated tumors.
† Value was compared between the surgical therapy with conventional indications group and the surgical therapy with nonconventional indications group.
x Value was compared between the endoscopic therapy with conventional indications group and the surgical therapy with conventional indications group.
jj Value was compared between the endoscopic therapy with non-conventional indications group and the surgical therapy with non-conventional indications group.
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Table 3
Characteristics of colorectal cancer patients with recurrence.
Age Sex
Initial
size, mm
Initial
location
∗
Morphology†
Initial treat.
Method Resection
Resection
margin Histology
SM invasion
depth, mm LVI
Recurrence
type
Months to
recurrence
1 78 M 30 Rectum IIa EMR Piecemeal Positive WD 2000 Positive Distant (lung) 13
2 53 F 25 Rectum Is EMR En bloc Negative MD 2000 Negative Local 19
3 74 F 30 Rectum IIa ESD En bloc Positive PD 500 Negative Local 40
4 72 M 15 Rectum Is EMR En bloc Negative MD 1000 Negative Local 46
5 70 M 10 Right Is EMR En bloc Negative WD 1000 Negative Distant (lung) 64
6 68 M 30 Rectum IIa LAR Negative MD 1750 Positive Local 8
7 63 F 20 Rectum Is LAR Negative MD 2000 Positive Distant (liver) 13
8 62 M 8 Rectum Is LAR Negative WD 1000 Positive Local 28
9 33 F 55 Rectum IIa LAR Negative WD 1000 Negative Distant (Peritoneum) 26
10 61 M 20 Rectum Is LAR Negative WD 3000 Negative Local 60
11 54 M 32 Left Is LHC Negative WD 2000 Negative Distant (liver) 23
12 51 M 70 Rectum IIa LAR Negative WD 1000 Negative Distant (lung) 45
13 60 M 20 Rectum Is LAR Negative MD 4000 Positive Local 37
14 49 M 12 Rectum Is LAR Negative MD 1000 Positive Distant (lung) 28
EMR= endoscopic mucosal resection, ESD= endoscopic submucosal dissection, F= female, LAR= lower anterior resection, LHC= left hemicolectomy, LVI= lymphovascular invasion, M=male, MD=
moderately differentiated, PD=poorly differentiated, SM= submucosa, WD=well differentiated.
∗
Right-sided colon was deﬁned as the region from the cecum to the transverse colon. Left-sided colon was deﬁned as the region from the splenic ﬂexure to the rectosigmoid junction. Rectum was deﬁned as the
region distal to the rectosigmoid junction to the anus.
†Morphology was classiﬁed using the Paris classiﬁcation.
Figure 2. Analysis of recurrence and mortality in T1 colorectal cancer (CRC)
patients using Kaplan–Meier curves stratiﬁed by initial therapeutic modality. (A)
The recurrence-free rate was not signiﬁcantly different between patients who
underwent initial endoscopic treatment and patients who underwent initial
surgery (P=0.471). (B) The survival rate was not signiﬁcantly different between
patients who underwent initial endoscopic treatment and patients who
underwent initial surgery (P=0.179).
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5In the total group of 428 patients, 14 patients (3.3%)
experienced CRC recurrence. Details for the patients who
experienced recurrence are reported in Table 3. For the 14
patients with recurrence, local recurrence was detected in 7
patients (50%) and distant metastasis was detected in 7 patients
(50%). The mean time to recurrence was 32.1 months. Ten
patients with recurrence were male, and 12 recurrence cases were
located at the rectum. Seven patients had sessile type disease and
5 patients had ﬂat type disease. Three patients developed
recurrence even after curative resection during the ﬁrst treatment
(EMR), and 1 patient developed recurrence even though the
initial endoscopic treatment met the CIs.
We used Kaplan–Meier curves stratiﬁed by initial therapeutic
modality to identify associations between initial therapeutic
modality and T1 CRC prognosis. The recurrence-free rate was
not signiﬁcantly different in patients treated with initial
endoscopic therapy versus patients treated with initial surgical
therapy (P=0.471) (Fig. 2A). Also, the mortality-free rate was
not signiﬁcantly different in patients treated with initial
endoscopic therapy versus patients treated with initial surgical
therapy (P=0.179) (Fig. 2B).
3.3. Risk factors for LNM in T1 CRC treated surgically
Among 347 patients who underwent surgery, 3 patients were
excluded because of the lack of the information about lymph
node metastasis. Among 344 patients who were analyzed, 89
patients belonged to the CI group and 258 patients belonged to
the NCI group. To identify factors related to LNM, we compared
clinical and pathological baseline characteristics. Clinical
baseline characteristics including age, sex, and T1 CRC location,
size, and morphology were not signiﬁcantly different between the
LNM-negative and LNM-positive groups. However, pathologi-
cal baseline characteristics were signiﬁcantly different. With
regard to histologic differentiation, poor differentiation was
more frequent in the LNM-positive group compared to the LNM-
negative group (10.5% vs. 1.2%; P<0.001). Additionally, LVI
occurred more frequently in the LNM-positive group than the
LNM-negative group (47.4% vs. 8.4%; P<0.001). However,
submucosal invasion depth >1000mm was not signiﬁcantly
Table 4
Univariate and multivariate analysis of factors related to lymph node metastasis in patients who underwent surgery because of
submucosal invasive colorectal cancer.
Univariate Multivariate
∗
Characteristics LNM-negative (n=325) LNM-positive (n=19) P Odds ratio (95% CI) P
Age, y (mean±SD) 61.8±10.2 66.0±10.2 0.081 1.051 (0.994–1.113) 0.081
Male, n (%) 194 (59.7) 13 (68.4) 0.450 1.067 (0.329–3.464) 0.914
Location, n (%) 0.683
Colon 185 (57.0) 9 (47.4)
Rectum 140 (43.1) 10 (52.6)
Size (mean±SD), mm 21.5±11.4 21.1±8.8 0.880 0.987 (0.926–1.052) 0.684
Size, mm, n (%) 0.497
<10 30 (9.2) 1 (5.3)
10–19 107 (32.9) 3 (15.8)
20–30 119 (36.6) 13 (68.4)
>30 69 (21.2) 2 (10.5)
Morphology, n (%)† 0.221
Is 176 (54.1) 9 (47.4)
Ip 24 (7.4) 4 (21.1)
IIa 114 (35.1) 6 (31.6)
IIa+ IIc 11 (3.4) 0 (0.0)
Histologic dif., n (%), (n=323, n=19)‡ <0.001
G1 152 (47.1) 2 (10.5) 1
G2 167 (51.7) 15 (78.9) 3.928 (0.826–18.691) 0.086
G3 4 (1.2) 2 (10.5) 45.945 (4.591–459.820) 0.001
LVI+, n (%), (n=308, n=19) 26 (8.4) 9 (47.4) <0.001 11.654 (3.638–37.336) <0.001
SM invasion >1000mm 204 (62.8) 16 (84.2) 0.058
SM invasion >1500mm 159 (48.9) 14 (73.7) 0.036 2.156 (0.677–6.864) 0.193
Variables are expressed as mean±SD or n (%). Histologic dif=histologic differentiation, LNM= lymph node metastasis, LVI= lymphovascular invasion, SD= standard deviation, SM= submucosa, WD=well
differentiated.
∗
Multivariate analysis used binomial logistic regression adjusted for age, sex, size of colorectal cancer, histologic differentiation, LVI, and SM invasion depth.
†Morphology was classiﬁed using the Paris classiﬁcation.
‡ G1 tumors are deﬁned as well differentiated, G2 tumors as moderately differentiated, G3 tumors as poorly differentiated.
Kim et al. Medicine (2016) 95:37 Medicineassociated with LNM (84.2% vs. 62.8%; P=0.058). Instead,
submucosal invasion depth >1000mm occurred signiﬁcantly
more frequently in the LNM-positive group compared to
the LNM-negative group (73.7% vs. 48.9%, P=0.036)
(Table 4).
In our multivariate analysis, which was adjusted for age, sex,
CRC size, histologic differentiation, LVI, and submucosal
invasion depth, LNM was related to positivity for LVI (odds
ratio [OR], 11.654; 95% conﬁdence interval [CI],
3.638–37.336; P<0.001) and poorly differentiated histology
(OR, 45.945; 95% CI, 4.591–459.820; P=0.001). However,
submucosal invasion depth >1500mm was not a signiﬁcantTable 5
The risk of lymph node metastasis and recurrence rate according to th
Conventional indications
Inclusion indication
Negative lateral/vertical margins O
No lymphovascular invasion O
G1 or G2 histologic dif.
∗
O
Submucosal invasion depth, mm 1000
Included patients n=155
Initial treatment modality Endoscopy: 80
Surgery: 75
Lymph node metastasis, n (%) 0 (0.0)
Recurrence, n (%) 3 (1.9)
Histologic dif=histologic differentiation.
∗
G1 tumors are deﬁned as well differentiated, G2 tumors deﬁned as moderately differentiated.
6predictor of LNM (OR, 2.156; 95% CI, 0.677–6.864; P=
0.193) (Table 4).3.4. The risk of LNM and recurrence rate according to the
depth of submucosal invasion
There was no LNM in the patients within conventional
indication.When the depth of submucosal invasion was extended
up to 1500mm, LNM was occurred (1 patient [0.5%]). In
addition, when the depth of submucosal invasion was extended
up to 2000mm, LNMwas increased even though recurrence rate
was not increased (4 patients [1.5%]) (Table 5).e depth of submucosal invasion in the nonconventional indication.
Nonconventional indication
O O
O O
O O
1500 2000
n=197 n=271
Endoscopy: 101 Endoscopy: 125
Surgery: 96 Surgery: 146
1 (0.5) 4 (1.5)
3 (1.5) 5 (1.8)
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Advances in colonoscopy devices and techniques have made it
possible to perform endoscopic resection of colorectal neoplasms,
including mucosal and submucosal cancer.[24,25] We found no
differences in the rate of surgical adverse events and outcomes
between patients treated with initial endoscopic therapy versus
patients treated with initial surgery. Therefore, clinicians have 2
options for the initial treatment of early CRC (ECC).
Importantly, sequential surgery after an initial endoscopy does
not increase surgical adverse events. Moreover, considering the
high rate of en bloc resection and the less invasive nature of
endoscopic approaches, it is reasonable to consider endoscopy as
an option for T1 CRC.
In this study, LNM was found in 19 of 428 patients (4.4%),
which is slightly lower than previous studies (6%–12%). Indeed,
some studies have suggested that up to 16% of patients with
localized submucosal invasive disease may already have
LNM.[12–15,26,27] This study had a lower rate of LNM because
it only included subjects with submucosal ECC that was clinical
stage T1N0 disease. Lack of gross lymph node enlargement on
computed tomography scans at the time of CRC diagnosis is a
characteristic of T1N0 disease. Accordingly, only micrometa-
static lymph node involvement was identiﬁed in this study.
Our ﬁndings that positive LVI and poorly differentiated
histology were associated with LNM are consistent with previous
studies of factors related to LNM. However, submucosal
invasion depth was not statistically signiﬁcantly related to
LNM. This result could indicate that submucosal invasion depth
is not the most effective predictor of LNM in patients with
submucosal ECC that is clinical stage T1N0 disease. Among the
19 patients with LNM, 1 patient had a submucosal invasion
depth of only 100mm. In contrast, 15 of the 144 ET-NCI group
patients (10.4%) could not undergo sequential operations
because of patient refusal or poor medical condition, and there
were no patients with CRC recurrence during the follow-up
period. Among these 15 patients, no patients had tumors with
poorly differentiated histology, 1 patient was LVI-positive, and
the other 14 had submucosal invasion depths >1000mm in
pathology analysis. Supporting these results, a few studies have
indicated that additional surgery and lymph node dissection are
not absolutely required for endoscopically resected pT1b CRC
(submucosal invasion depth ≥1000mm) in cases where vascular
invasion, poorly differentiated adenocarcinoma, signet ring cell
carcinoma, mucinous carcinoma, and grade 2/3 budding at the
deepest part of the submucosal invasion are not detected, as these
tumors have a very low rate of LNM (1%–2%).[28,29] However,
the rate of LNM in these studies was not zero.
Considering these ﬁndings, we can see that the present CIs are
not perfect when it comes to selecting the initial treatment for T1
CRC. Hopefully, in the near future, novel imaging technologies
(e.g., confocal endomicroscopy) coupled with increased patho-
logical recognition of high-risk markers for LNM will lead to
improved staging and clinical care. For example, expert
pathologists recently emphasized that tumor budding is an
independent prognostic indicator for risk of lymph node
involvement, especially in early stage CRC.[30] The description
of tumor budding is attributed to Imai, who ﬁrst postulated that
this particular pathological feature of invasive colon cancer
represented a sudden or rapid growth of the leading or invasive
edge of the carcinoma and is partially related to interactions
between epithelial and mesenchymal elements at the tumor
margin.[30] Accumulated evidence indicates that tumor budding7as well as high tumor grade and LVI are independent risk factors
for LNM in patients with submucosally invasive colon
cancer.[31,32]
The strength of this study is that it is the ﬁrst analysis to
speciﬁcally examine patients with submucosal ECC that was
initially clinical stage T1N0 disease to evaluate outcomes of
endoscopic treatment versus surgery and to determine the
optimal indications for endoscopic treatment. Additionally, the
mean follow-up period was >3.5 years, which is long enough to
evaluate long-term prognosis.
A limitation of this study is its retrospective nature. Insufﬁcient
record-keeping could give rise to inaccurate information about
medications. Therefore, a prospective study that includes a large
number of patients is needed to evaluate the outcomes of
endoscopic treatment and to determine the optimal indications
for endoscopic treatment in T1 CRC patients.
In conclusion, T1CRCpatients treated by endoscopic resection,
surgical resection, or both, depending on the CIs, had good long-
term clinical outcomes.However, it might not be safe to extend the
present CIs for endoscopic therapy in T1 CRC. For patients with
T1CRC lesions that donot satisfy theCIs,we strongly recommend
adequate surgical resection with lymph node dissection.Acknowledgments
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